Guerbet's innovation, Eluciremâ„¢ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results